AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Ectonucleoside triphosphate diphosphohydrolase 3 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Ectonucleoside triphosphate diphosphohydrolase 3 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Ectonucleoside triphosphate diphosphohydrolase 3, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Ectonucleoside triphosphate diphosphohydrolase 3. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Ectonucleoside triphosphate diphosphohydrolase 3. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Ectonucleoside triphosphate diphosphohydrolase 3 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Ectonucleoside triphosphate diphosphohydrolase 3
partner:
Reaxense
upacc:
O75355
UPID:
ENTP3_HUMAN
Alternative names:
CD39 antigen-like 3; Ecto-ATP diphosphohydrolase 3; Ecto-apyrase 3; HB6
Alternative UPACC:
O75355; B2R8D0; G5E9N0; O60495; Q8N6K2
Background:
Ectonucleoside triphosphate diphosphohydrolase 3, known by alternative names such as CD39 antigen-like 3, Ecto-ATP diphosphohydrolase 3, Ecto-apyrase 3, and HB6, plays a crucial role in cellular processes by preferring the hydrolysis of ATP over ADP. This specificity indicates a unique enzymatic activity that could be pivotal in regulating extracellular ATP levels, a key molecule in energy transfer and signaling.
Therapeutic significance:
Understanding the role of Ectonucleoside triphosphate diphosphohydrolase 3 could open doors to potential therapeutic strategies. Its unique preference for ATP hydrolysis over ADP suggests a significant function in maintaining cellular energy balance and signaling, making it a compelling target for drug discovery efforts aimed at modulating energy metabolism and signal transduction pathways.
